The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma
Article first published online: 30 NOV 2007
Copyright © 2007 Wiley-Liss, Inc.
International Journal of Cancer
Volume 122, Issue 6, pages 1207–1213, 15 March 2008
How to Cite
Pfister, S., Rea, S., Taipale, M., Mendrzyk, F., Straub, B., Ittrich, C., Thuerigen, O., Sinn, H. P., Akhtar, A. and Lichter, P. (2008), The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int. J. Cancer, 122: 1207–1213. doi: 10.1002/ijc.23283
- Issue published online: 21 JAN 2008
- Article first published online: 30 NOV 2007
- Manuscript Accepted: 26 SEP 2007
- Manuscript Received: 2 AUG 2007
- Deutsche Forschungs-Gemeinschaft: Sonderforschungsbereich “Transregio TR5”
This article contains supplementary material available via the Internet at http://www.interscience.wiley.com/jpages/0020-7136/suppmat .
|ijc23283-Supplementary_Table_1.doc||96K||Supporting Information file ijc23283-Supplementary_Table_1.doc|
|ijc23283-Supplementary_Table_2.doc||60K||Supporting Information file ijc23283-Supplementary_Table_2.doc|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.